小智港股覆盤 | 9月13日
今日,港股三大指數漲跌互現。截止收盤,恆生指數跌0.18%,報19326點。國企指數漲0.07%,報6633點。恆生科技指數跌0.2%,報4069點。市場約793只個股上漲,841只個股下跌。成交額突破949.86億港幣,和昨天同期相比增長2.94%。南下資金淨流入21.82億港幣。

盤面上,汽車板塊集體拉昇。蔚來-SW漲超16%;比亞迪股份、長城汽車、小鵬汽車-W等多股漲超2%;北京汽車漲超1%。瑞信:蔚來末季銷量目標逾6萬輛,管理層料本季毛利率按季改善。

餐飲酒店板塊跟隨走強。美高梅中國漲超7%;呷哺呷哺、永利澳門、澳博控股等多股漲超6%;國藥科技股份漲超4%。呷哺呷哺漲超6%領漲餐飲股,中秋假期帶動餐飲消費回暖;永利澳門高漲逾8%,附屬向澳門政府遞交博彩批給標書。

CRO板塊暴跌。藥明生物跌超19%;藥明康德跌超16%;康龍化成跌超14%;泰格醫藥跌超9%;方達控股跌超6%。藥明生物漲超4%領漲CRO概念,機構看好醫藥行業財報築底回升;國泰君安首予康龍化成“買入”評級,目標價70.31港元;國泰君安(香港):予泰格醫藥“買入”評級,目標價100.13港元。

生物科技板塊多數下跌。樂普生物-B跌超42%;創勝集團-B跌超11%;開拓藥業-B跌超8%;藥明巨諾-B跌超7%;和鉑醫藥-B跌超6%。樂普生物-B午後曾飆近3.9倍高見31.8元,本週一起獲深交所調入港股通名單;創勝集團於ESMO上公佈TST001(Osemitamab)項目進展;開拓藥業-B完成發行1991萬股認購股份。

包裝印刷板塊跌幅居前。透雲生物跌超24%;TEAMWAY INTL GP跌超8%;正業國際跌超7%;冠均國際控股跌超6%;合豐集團跌超5%。

uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.